ArticleDiabetes care2012
A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Counterpoint.
Article in Diabetes care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- Glycated albumin: An old yet new biomarker in people with diabetes and the potential for novel applications.Journal of diabetes investigation · 2026Review
- The effect of icodextrin on peritoneal dialysis patients with congestive heart failure: a time-varying exposure design and target trial emulation approach.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Importance of food plants in the prevention and treatment of diabetes in Cameroon.Bioactive compounds in health and disease · 2019Article
- Development of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease.Diabetology international · 2018Article
- Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.The Journal of clinical endocrinology and metabolism · 2017Review
- Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.Journal of the American Society of Nephrology : JASN · 2017Review
- Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes.Diabetes care · 2017Article
- Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? No, We Should Never Again Compromise Safety!Diabetes care · 2016Article
- Diabetes mellitus and renal failure: Prevention and management.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2015Review
- Management of Hyperglycemia in Diabetic Kidney Disease.Diabetes spectrum : a publication of the American Diabetes Association · 2015Article
- Management of diabetes mellitus in patients with chronic kidney disease.Clinical diabetes and endocrinology · 2015Article
- Diabetic kidney disease: a report from an ADA Consensus Conference.Diabetes care · 2014Article
- Updates on the management of diabetes in dialysis patients.Seminars in dialysis · 2014Review
- Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients.Diabetes care · 2013Article
- Measurement of Hba(1C) in patients with chronic renal failure.Clinica chimica acta; international journal of clinical chemistry · 2013Article
- Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes.Current diabetes reports · 2013Review
- Diabetes Care: “state of the union”.Diabetes care · 2013Article
- Dietary restrictions in dialysis patients: is there anything left to eat?Seminars in dialysisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Chronic kidney disease remains as one of the major complications for individuals with diabetes and contributes to considerable morbidity. Individuals subjected to dialysis therapy, half of whom are diabetic, experience a mortality of ~20% per year. Understanding factors related to mortality remains a priority. Outside of dialysis units, A1C is unquestioned as the "gold standard" for glycemic control. In the recent past, however, there is evidence in large cohorts of diabetic dialysis patients that A1C at both the higher and lower levels was associated with mortality. Given the unique conditions associated with the metabolic dysregulation in dialysis patients, there is a critical need to identify accurate assays to monitor glycemic control to relate to cardiovascular endpoints. In this two-part point-counterpoint narrative, Drs. Freedman and Kalantar-Zadeh take opposing views on the utility of A1C in relation to cardiovascular disease and survival and as to consideration of use of other short-term markers in glycemia. In the narrative preceeding this counterpoint, Dr. Freedman suggests that glycated albumin may be the preferred glycemic marker in dialysis subjects. In the counterpoint narrative below, Dr. Kalantar-Zadeh defends the use of A1C as the unquestioned gold standard for glycemic management in dialysis subjects.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.